Prognostic Value of Pre-Treatment [18F]FDG PET/CT Texture Analysis in Undifferentiated Soft-Tissue Sarcoma.
18F-FDG
PET/CT
predictive value
radiomics
undifferentiated soft-tissue sarcoma
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
29 Dec 2022
29 Dec 2022
Historique:
received:
25
10
2022
revised:
19
12
2022
accepted:
27
12
2022
entrez:
8
1
2023
pubmed:
9
1
2023
medline:
9
1
2023
Statut:
epublish
Résumé
Undifferentiated soft-tissue sarcomas (USTS) are one of the most common sarcoma histotypes in adults. The standard of care is surgical excision plus adjuvant radiotherapy, while the use of perioperative chemotherapy is still controversial. The aim of this study was to investigate the value of pre-treatment [18F]FDG PET/CT conventional metrics and textural features in predicting disease-free survival (DFS) and overall survival (OS) in patients with USTS of the limbs and trunk. [18F]FDG PET/CT scans of 51 consecutive patients with locally advanced USTS were retrospectively evaluated. Conventional and textural PET parameters were analysed and tested as predictive factors for DFS and OS. During a median follow up of 50.7 months, 23 (45.1%) and 29 (56.9%) patients had death or disease progression, respectively. Univariate analysis revealed a significant association for perioperative treatment, PET volumetric parameters and the textural feature GLCM_correlation with DFS and OS. In multivariate analysis, perioperative treatment and GLCM_correlation were the only independent factors, allowing stratification of the population into three different prognostic classes. GLCM_correlation can identify USTS at high risk of relapse and death, thus helping to optimize the perioperative treatment of patients.
Sections du résumé
BACKGROUND
BACKGROUND
Undifferentiated soft-tissue sarcomas (USTS) are one of the most common sarcoma histotypes in adults. The standard of care is surgical excision plus adjuvant radiotherapy, while the use of perioperative chemotherapy is still controversial. The aim of this study was to investigate the value of pre-treatment [18F]FDG PET/CT conventional metrics and textural features in predicting disease-free survival (DFS) and overall survival (OS) in patients with USTS of the limbs and trunk.
METHODS
METHODS
[18F]FDG PET/CT scans of 51 consecutive patients with locally advanced USTS were retrospectively evaluated. Conventional and textural PET parameters were analysed and tested as predictive factors for DFS and OS.
RESULTS
RESULTS
During a median follow up of 50.7 months, 23 (45.1%) and 29 (56.9%) patients had death or disease progression, respectively. Univariate analysis revealed a significant association for perioperative treatment, PET volumetric parameters and the textural feature GLCM_correlation with DFS and OS. In multivariate analysis, perioperative treatment and GLCM_correlation were the only independent factors, allowing stratification of the population into three different prognostic classes.
CONCLUSION
CONCLUSIONS
GLCM_correlation can identify USTS at high risk of relapse and death, thus helping to optimize the perioperative treatment of patients.
Identifiants
pubmed: 36615079
pii: jcm12010279
doi: 10.3390/jcm12010279
pmc: PMC9821547
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Cancer. 2012 Dec 1;118(23):5857-66
pubmed: 22605504
Head Neck. 2019 Feb;41(2):495-502
pubmed: 30549149
Nucl Med Mol Imaging. 2015 Mar;49(1):33-41
pubmed: 25774236
Life (Basel). 2021 Aug 24;11(9):
pubmed: 34575018
Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1721-1731
pubmed: 28409221
Clin Sarcoma Res. 2018 Apr 09;8:9
pubmed: 30116519
J Nucl Med. 2014 Mar;55(3):414-22
pubmed: 24549286
Head Neck. 2020 Dec;42(12):3744-3754
pubmed: 32914474
Contrast Media Mol Imaging. 2021 Nov 22;2021:7528971
pubmed: 34887713
Ann Oncol. 2021 Nov;32(11):1348-1365
pubmed: 34303806
Eur J Nucl Med Mol Imaging. 2013 Dec;40(12):1836-42
pubmed: 23880967
J Clin Oncol. 2018 Jan 10;36(2):160-167
pubmed: 29220302
Am J Clin Oncol. 2002 Feb;25(1):16-22
pubmed: 11823689
Medicine (Baltimore). 2015 Jul;94(28):e1142
pubmed: 26181552
PET Clin. 2018 Oct;13(4):609-621
pubmed: 30219191
Lancet Oncol. 2016 May;17(5):671-80
pubmed: 27068860
Eur J Nucl Med Mol Imaging. 2019 Dec;46(13):2790-2799
pubmed: 31482428
ANZ J Surg. 2019 Sep;89(9):1045-1050
pubmed: 31364245
J Surg Oncol. 2014 Apr;109(5):410-4
pubmed: 24310279
Cancers (Basel). 2022 Jan 27;14(3):
pubmed: 35158904
Cancer. 1996 May 1;77(9):1823-30
pubmed: 8646680
J Natl Compr Canc Netw. 2015 Nov;13(11):1366-74
pubmed: 26553766
J Clin Med. 2020 Aug 06;9(8):
pubmed: 32781683
Skeletal Radiol. 2014 May;43(5):641-8
pubmed: 24531303
Medicine (Baltimore). 2017 Feb;96(6):e5913
pubmed: 28178131
Int J Cancer. 1984 Jan 15;33(1):37-42
pubmed: 6693192
Cancer Res. 2018 Aug 15;78(16):4786-4789
pubmed: 29959149
Ann Surg. 1982 Sep;196(3):305-15
pubmed: 7114936
Ann Surg Oncol. 2014 Aug;21(8):2484-9
pubmed: 24756814
CA Cancer J Clin. 2020 May;70(3):200-229
pubmed: 32275330
Eur J Nucl Med Mol Imaging. 2016 Jul;43(8):1453-60
pubmed: 26830299